

HR 5668

MODERN Labeling Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 24, 2020

Current Status: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and

Latest Action: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Nov 18, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/5668>

Sponsor

Name: Rep. Matsui, Doris O. [D-CA-6]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		Jan 24, 2020
Rep. Taylor, Van [R-TX-3]	R · TX		Nov 16, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Markup by	Mar 11, 2020
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Nov 18, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4796	Related bill	Oct 5, 2020: Read twice and referred to the Committee on Finance.
116 HR 8527	Related bill	Oct 2, 2020: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
116 S 1895	Related bill	Jul 8, 2019: Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.
116 S 1897	Related bill	Jun 19, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Making Objective Drug Evidence Revisions for New Labeling Act of 2020 or the MODERN Labeling Act of 2020

This bill authorizes the Food and Drug Administration (FDA) to require updates to outdated labels for certain generic drugs if the updates will provide a public health benefit. Generally, the FDA may use this authority to update the label of a generic version of a brand-name drug that has been withdrawn from the market for reasons other than safety or effectiveness.

Actions Timeline

- **Nov 18, 2020:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Nov 17, 2020:** Mr. Pallone moved to suspend the rules and pass the bill, as amended.
- **Nov 17, 2020:** Considered under suspension of the rules. (consideration: CR H5805-5807)
- **Nov 17, 2020:** DEBATE - The House proceeded with forty minutes of debate on H.R. 5668.
- **Nov 17, 2020:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5805-5806)
- **Nov 17, 2020:** On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)
- **Nov 17, 2020:** Motion to reconsider laid on the table Agreed to without objection.
- **Nov 16, 2020:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.
- **Nov 16, 2020:** Placed on the Union Calendar, Calendar No. 471.
- **Jul 15, 2020:** Committee Consideration and Mark-up Session Held.
- **Jul 15, 2020:** Ordered to be Reported (Amended) by Voice Vote.
- **Mar 11, 2020:** Ordered to be Reported (Amended) by Voice Vote.
- **Mar 11, 2020:** Subcommittee Consideration and Mark-up Session Held.
- **Jan 25, 2020:** Referred to the Subcommittee on Health.
- **Jan 24, 2020:** Introduced in House
- **Jan 24, 2020:** Referred to the House Committee on Energy and Commerce.